Progesterone transdermal - Transdermal Delivery Solutions

Drug Profile

Progesterone transdermal - Transdermal Delivery Solutions

Alternative Names: Progesterone spray - Transdermal Delivery Solutions; Progesterone TDS®

Latest Information Update: 27 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transdermal Delivery Solutions Corp
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Menopausal syndrome; Premenstrual syndrome

Most Recent Events

  • 27 May 2016 Progesterone is still in non-clinical development for Menopausal and Premenstrual syndrome (Company website - May 2016)
  • 09 May 2002 Preclinical trials in Menopausal syndrome in USA (Transdermal)
  • 09 May 2002 Preclinical trials in Premenstrual syndrome in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top